← Leaderboards
Tyler Steven Beyett
Dana-Farber Cancer Inst
$195,654
Attributed
$195,654
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $66.4K · FY2020–22$100K$75K$50K$25K$0
'20
'21
'22
Funding mix
By agency
NIH$195,654 · 1
By mechanism
F32$195,654 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Michael J Eck$25,871,961
- Bruce E. Johnson$13,594,149
- Nathanael Schiander Gray$36,761,550
- Lee Marshall Nadler$396,612,225
- Lorelei Mucci$13,743,245
Others in their field
Other Emerging Leaders on “Allosteric Site”
- Gian Luca Araldi · Avanti Biosciences, Inc.$3,500,253
- Gregory Bowman · University Of Pennsylvania$2,946,112
- Esma Alp · Kalocyte, Inc.$2,518,060
- Harish Vashisth · University Of New Hampshire$2,485,989
- Robert Joseph Tomko · Florida State University$2,448,654
- Doeke Romke Hekstra · Harvard University$2,447,915
Research focus
Allosteric SiteAffectAreaAssay DevelopmentApplications GrantsBinding SitesBiochemicalBudgetsCancer BiologyCancer CellBindingCancer TypeCellular BiologyChargeChemistryClinicClinically RelevantCollaborationsCombined Modality TherapyComplexCrystallizationDana-Farber Cancer InstituteCancer PharmacologyDrug Resistance
Grant awards (3)
Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer$64,338
F32 · FY2022 · CA · contact PI
Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer$66,390
F32 · FY2021 · CA · contact PI
Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer$64,926
F32 · FY2020 · CA · contact PI